Spotting-based differentiation of functional dopaminergic progenitors from human pluripotent stem cells

Jisun Kim, Jeha Jeon, Bin Song, Nayeon Lee, Sanghyeok Ko, Young Cha, Pierre Leblanc, Hyemyung Seo, Kwang-Soo Kim

Published: 2022-02-08 DOI: 10.1038/s41596-021-00673-4

Spotting-based differentiation

Extended

Extended Data Fig. 1 hPSC spotting condition optimization for H9 hESC cells.

Extended Data Fig. 2 hPSC spotting condition optimization for H9 hESC cells.

The effects of cell number per spot and the number of spots per plate were determined for optimization of spotting condition. Cell loss, cell harvest, the percentage of dead cells in the final harvest and the ratio of cell loss per cell yield are shown.

Source data

Extended Data Fig. 3 Effects of H9 hESC spotting conditions on viability and gene expression.

Source data

Extended Data Fig. 4 Effects of C4 hiPSC spotting conditions on viability and gene expression.

a – c , The health of H9 hESCs and C4 hiPSCs were examined by TUNEL staining ( a ), expression of apoptosis marker cleaved caspase-3 ( b ) and expression of apoptosis marker genes ( c ), as described in ref. 10 . Scale bars, 100 µm.

Source data

Extended Data Fig. 5 Characterization of H9-derived mDAPs by immunofluorescence on day 28 following spotting and monolayer culture.

The antibodies for FOXA2, LMX1A and TH were used to stain mDAPs, and the antibodies for cleaved caspase-3 were used to stain apoptotic cells. Scale bars, 100 µm.

Supplementary information

Supplementary Information

Supplementary Tables 1 and 2.

Tutorial: guidelines for the computational analysis of single-cell RNA sequencing data

ProBac-seq, a bacterial single-cell RNA sequencing methodology using droplet microfluidics and large oligonucleotide probe sets

References

Extended
Supplementary information

Chambers, S. M. et al. Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling. Nat. Biotechnol. 27, 275–280 (2009).
de Lau, L. M. & Breteler, M. M. Epidemiology of Parkinson’s disease. Lancet Neurol. 5, 525–535 (2006).
Kefalopoulou, Z. et al. Long-term clinical outcome of fetal cell transplantation for Parkinson disease: two case reports. JAMA Neurol. 71, 83–87 (2014).
Piccini, P. et al. Dopamine release from nigral transplants visualized in vivo in a Parkinson’s patient. Nat. Neurosci. 2, 1137–1140 (1999).
Lindvall, O. Developing dopaminergic cell therapy for Parkinson’s disease—give up or move forward? Mov. Disord. 28, 268–273 (2013).
Barker, R. A., Barrett, J., Mason, S. L. & Bjorklund, A. Fetal dopaminergic transplantation trials and the future of neural grafting in Parkinson’s disease. Lancet Neurol. 12, 84–91 (2013).
Sonntag, K. C. et al. Pluripotent stem cell-based therapy for Parkinson’s disease: current status and future prospects. Prog. Neurobiol. 168, 1–20 (2018).
Parmar, M., Grealish, S. & Henchcliffe, C. The future of stem cell therapies for Parkinson disease. Nat. Rev. Neurosci. 21, 103–115 (2020).
Barker, R. A., Drouin-Ouellet, J. & Parmar, M. Cell-based therapies for Parkinson disease-past insights and future potential. Nat. Rev. Neurol. 11, 492–503 (2015).
Lindvall, O. & Bjorklund, A. Cell therapeutics in Parkinson’s disease. Neurotherapeutics 8, 539–548 (2011).
Song, B. et al. Human autologous iPSC-derived dopaminergic progenitors restore motor function in Parkinson’s disease models. J. Clin. Invest. 130, 904–920 (2020).
Schweitzer, J. S. et al. Personalized iPSC-derived dopamine progenitor cells for Parkinson’s disease. N. Engl. J. Med. 382, 1926–1932 (2020).
Arenas, E., Denham, M. & Villaescusa, J. C. How to make a midbrain dopaminergic neuron. Development 142, 1918–1936 (2015).
Tao, Y. & Zhang, S. C. Neural subtype specification from human pluripotent stem cells. Cell Stem Cell 19, 573–586 (2016).
Kittappa, R., Chang, W. W., Awatramani, R. B. & McKay, R. D. The foxa2 gene controls the birth and spontaneous degeneration of dopamine neurons in old age. PLoS Biol. 5, e325 (2007).
Chung, S. et al. Wnt1-lmx1a forms a novel autoregulatory loop and controls midbrain dopaminergic differentiation synergistically with the SHH–FoxA2 pathway. Cell Stem Cell 5, 646–658 (2009).
Joksimovic, M. et al. Wnt antagonism of Shh facilitates midbrain floor plate neurogenesis. Nat. Neurosci. 12, 125–131 (2009).
Bonilla, S. et al. Identification of midbrain floor plate radial glia-like cells as dopaminergic progenitors. Glia 56, 809–820 (2008).
Ono, Y. et al. Differences in neurogenic potential in floor plate cells along an anteroposterior location: midbrain dopaminergic neurons originate from mesencephalic floor plate cells. Development 134, 3213–3225 (2007).
Kriks, S. et al. Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson’s disease. Nature 480, 547–551 (2011).
Morizane, A., Doi, D., Kikuchi, T., Nishimura, K. & Takahashi, J. Small-molecule inhibitors of bone morphogenic protein and activin/nodal signals promote highly efficient neural induction from human pluripotent stem cells. J. Neurosci. Res. 89, 117–126 (2011).
Doi, D. et al. Isolation of human induced pluripotent stem cell-derived dopaminergic progenitors by cell sorting for successful transplantation. Stem Cell Rep. 2, 337–350 (2014).
Kirkeby, A. et al. Generation of regionally specified neural progenitors and functional neurons from human embryonic stem cells under defined conditions. Cell Rep. 1, 703–714 (2012).
Xi, J. et al. Specification of midbrain dopamine neurons from primate pluripotent stem cells. Stem Cells 30, 1655–1663 (2012).
Xiong, M. et al. Human stem cell-derived neurons repair circuits and restore neural function. Cell Stem Cell 28, 112–126 e116 (2021).
Kim, T. W. et al. Biphasic activation of WNT signaling facilitates the derivation of midbrain dopamine neurons from hESCs for translational use. Cell Stem Cell 28, 343–355 e345 (2021).
Gantner, C. W., Cota-Coronado, A., Thompson, L. H. & Parish, C. L. An optimized protocol for the generation of midbrain dopamine neurons under defined conditions. STAR Protoc. 1, 100065 (2020).
Knusel, B. et al. Promotion of central cholinergic and dopaminergic neuron differentiation by brain-derived neurotrophic factor but not neurotrophin 3. Proc. Natl Acad. Sci. USA 88, 961–965 (1991).
Lin, L. F., Doherty, D. H., Lile, J. D., Bektesh, S. & Collins, F. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 260, 1130–1132 (1993).
Ye, W., Shimamura, K., Rubenstein, J. L., Hynes, M. A. & Rosenthal, A. FGF and Shh signals control dopaminergic and serotonergic cell fate in the anterior neural plate. Cell 93, 755–766 (1998).
Madl, C. M., Heilshorn, S. C. & Blau, H. M. Bioengineering strategies to accelerate stem cell therapeutics. Nature 557, 335–342 (2018).
Engler, A. J., Sen, S., Sweeney, H. L. & Discher, D. E. Matrix elasticity directs stem cell lineage specification. Cell 126, 677–689 (2006).
Ko, J. Y., Lee, J. Y., Park, C. H. & Lee, S. H. Effect of cell-density on in-vitro dopaminergic differentiation of mesencephalic precursor cells. Neuroreport 16, 499–503 (2005).
Bolognin, S. et al. 3D Cultures of Parkinson’s disease–specific dopaminergic neurons for high content phenotyping and drug testing. Adv. Sci. 6, 1800927 (2019).
Jo, J. et al. Midbrain-like organoids from human pluripotent stem cells contain functional dopaminergic and neuromelanin-producing neurons. Cell Stem Cell 19, 248–257 (2016).
Adil, M. M. & Schaffer, D. V. hPSC-derived midbrain dopaminergic neurons generated in a scalable 3-D biomaterial. Curr. Protoc. Stem Cell Biol. 44, 2D 21 21–22D 21 17 (2018).
Piao, J. et al. Preclinical efficacy and safety of a human embryonic stem cell-derived midbrain dopamine progenitor product, MSK-DA01. Cell Stem Cell 28, 217–229 e217 (2021).
Nolbrant, S., Heuer, A., Parmar, M. & Kirkeby, A. Generation of high-purity human ventral midbrain dopaminergic progenitors for in vitro maturation and intracerebral transplantation. Nat. Protoc. 12, 1962–1979 (2017).
Kirkeby, A. et al. Predictive markers guide differentiation to improve graft outcome in clinical translation of hESC-based therapy for Parkinson’s disease. Cell Stem Cell 20, 135–148 (2017).
Doi, D. et al. Pre-clinical study of induced pluripotent stem cell-derived dopaminergic progenitor cells for Parkinson’s disease. Nat. Commun. 11, 3369 (2020).
Lee, M. O. et al. Inhibition of pluripotent stem cell-derived teratoma formation by small molecules. Proc. Natl Acad. Sci. USA 110, E3281–E3290 (2013).
Kirkeby, A., Parmar, M. & Barker, R. A. Strategies for bringing stem cell-derived dopamine neurons to the clinic: a European approach (STEM-PD). Prog. Brain Res. 230, 165–190 (2017).
Kikuchi, T. et al. Idiopathic Parkinson’s disease patient-derived induced pluripotent stem cells function as midbrain dopaminergic neurons in rodent brains. J. Neurosci. Res. 95, 1829–1837 (2017).
Kikuchi, T. et al. Human iPS cell-derived dopaminergic neurons function in a primate Parkinson’s disease model. Nature 548, 592–596 (2017).
Chen, Y. et al. Chemical control of grafted human PSC-derived neurons in a mouse model of Parkinson’s disease. Cell Stem Cell 18, 817–826 (2016).
Williams, G. T. Programmed cell death: apoptosis and oncogenesis. Cell 65, 1097–1098 (1991).
Fisher, D. E. Apoptosis in cancer therapy: crossing the threshold. Cell 78, 539–542 (1994).
Roos, W. P. & Kaina, B. DNA damage-induced cell death by apoptosis. Trends Mol. Med. 12, 440–450 (2006).

Spotting-based differentiation of functional dopaminergic progenitors from human pluripotent stem cells

Extended

Supplementary information

推荐阅读